- トップ
- > 研究者・企業の方へ
- > 臨床研究センターについて
- > 事業・実績
- > 論文
論文
掛江 直子
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | 掛江直子: 第9章 胎児・小児をめぐる諸問題. 改訂版 生命倫理・医事法，医療科学社, 2018: 147-164. |
| 2 | 掛江直子: 新・皮膚科セミナリウム 変貌する難病診療の最前線2.小児慢性特定疾病対策のこれから. 日本皮膚科学会雑誌 第128巻第1号，日本皮膚科学会，2018: 41-49. |
| 3 | 掛江直子: 小児医療における意思決定. 日本医事法学会編「年報医事法学32」, 日本評論社, 2017: 49-56. |
| 4 | 掛江直子: 染色体・遺伝子検査-1. 総論「染色体, 遺伝子検査の倫理」. 小児臨床検査のポイント2017 小児内科2017vol.49増刊号, 東京医学社, 2017: 666-672． |
| 5 | Kenji Takehara , Yoshiyuki Tachibana, Keiko Yoshida, Rintaro Mori, Naoko Kakee, Takahiko Kubo. Prevalence trends of pre-and postnatal depression in Japanese women: A population-based longitudinal study. Journal of Affective Disorders. 2018; 225: 389-394. |
| 6 | Hatoko Sasaki, Naoko Kakee, Naho Morisaki, Rintaro Mori, Ulrike Ravens-Sieberer, Monika Bullinger: Assessing health-related quality of life in young Japanese childrenwith chronic conditions: Preliminary validation of the DISABKIDS smiley measure. BMC Pediatrics. 2017: doi:10.1186/s12887-017-0854-4. Published online. |
| 7 | Kenji Takehara, Maiko Suto, Naoko Kakee, Yoshiyuki Tachibana, Rintaro Mori. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child Abuse & Neglect. 2017; 70: https://doi.org/10.1016/j.chiabu.2017.06.011 |
| 8 | 掛江直子: 新しい小児慢性特定疾病対策について ①新制度の概要とおもな変更点, 小児慢性特定疾病 診断の手引き, 診断と治療社, 2016: 2-5. |
| 9 | 小児慢性特定疾病情報室（掛江直子 他）編集：小児慢性特定疾病 診断の手引き, 診断と治療社, 2016. |
| 10 | 掛江直子: よりよい小児がん臨床研究のために求められる研究のあり方「小児がん臨床研究における研究倫理のあり方と特徴」. よくわかる臨床研究～小児がん～, 医薬ジャーナル社, 2016: 160-169 |
| 11 | 掛江直子: Ⅰ.総論「2.小児慢性特定疾病対策と難病対策－法改正ならびに新法成立でどのように変わったか－」, 小児科臨床, 日本小児医事出版社, 69(4), 2016: 505-514 |
佐古 まゆみ
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol. 2020 ;35:17-24 |
| 2 | Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial) . BMC Nephrol. 2019 Aug 2;20(1):293. doi: 10.1186/s12882-019-1470-3. |
| 3 | Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Ohya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trialAllergol Int. 2019 ; 68:335-341 |
| 4 | Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, Honda M, Kamei K, Ishikura K, Ito S, Kaito H, Tanaka R, Nozu K, Nakamura H, Ohashi Y, Iijima K, Yoshikawa N; Japanese Study Group of Kidney Disease in Children (JSKDC). Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol. 2019 ;34:837-846. |
| 5 | Osumi T, Tomizawa D, Kawai T, Sako M, Inoue E, Takimoto T, Tamura E, Uchiyama T, Imadome KI, Taniguchi M, Shirai R, Yoshida M, Ando R, Tsumura Y, Fuji H, Matsumoto K, Shioda Y, Kiyotani C, Terashima K, Onodera M, Matsumoto K, Kato M. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. 2019 ;54:168-172 |
| 6 | Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrol. 2018 Nov 1;19(1):302. doi: 10.1186/s12882-018-1099-7. |
| 7 | Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N; Japanese Pediatric IgA Nephropathy Treatment Study Group. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol. 2018 ;33:2103-2112 |
| 8 | Iijima K, Sako M, Kamei K, Nozu K. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol. 2018 ;33:1449-1455 |
| 9 | Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N; Japanese Study Group of Kidney Disease in Children (JSKDC). Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial) BMC Nephrol. 2018 Sep 10;19(1):223. doi: 10.1186/s12882-018-1033-z. |
| 10 | Kubota W, Honda M, Okada H, Hattori M, Iwano M, Akioka Y, Ashida A, Kawasaki Y, Kiyomoto H, Sako M, Terada Y, Hirano D, Fujieda M, Fujimoto S, Masaki T, Ito S, Uemura O, Gotoh Y, Komatsu Y, Nishi S, Maru M, Narita I, Maruyama S: A consensus statement on health-care transition of patients with childhood-onset chronic kidney diseases: providing adequate medical care in adolescence and young adulthood. Clin Exp Nephrol. 2018 ;22:743-751 |
竹原 健二
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Takehara K, Suto M, Kato T. Parental psychological distress in the postnatal period in Japan: a population-based analysis of a national cross-sectional survey. Scientific Reports. 2020;10(1). |
| 2 | Balogun, O. O., Tomo, C. K., Mochida, K., Mikami, M., da Rosa Vasconcelos, H., Neves, I., . . . Takehara, K. Impact of the Maternal and Child Health handbook in Angola for improving continuum of care and other maternal and child health indicators: study protocol for a cluster randomised controlled trial. Trials. 2020;21(1):737. |
| 3 | Takehara K, Ganchimeg T, Kikuchi A, Gundegmaa L, Altantsetseg L, Aoki A, et al. The effectiveness of exercise intervention for academic achievement, cognitive function, and physical health among children in Mongolia: a cluster RCT study protocol. BMC public health. 2019;19(1):697. |
| 4 | Dagvadorj A, Corsi DJ, Sumya N, Muldoon K, Wen SW, Takehara K, et al. Prevalence and determinants of mental health problems among children in Mongolia: A population-based birth cohort. Global Epidemiology. 2019;1:100011. |
| 5 | Takehara K, Tachibana Y, Yoshida K, Mori R, Kakee N, Kubo T. Prevalence trends of pre- and postnatal depression in Japanese women: A population-based longitudinal study. Journal of affective disorders. 2018;225:389-94. |
| 6 | Dagvadorj A, Ganbaatar D, O OB, Yonemoto N, Bavuusuren B, Takehara K, et al. Maternal socio-demographic and psychological predictors for risk of developmental delays among young children in Mongolia. BMC pediatrics. 2018;18(1):68. |
| 7 | Hikita N, Haruna M, Matsuzaki M, Shiraishi M, Takehara K, Dagvadorj A, et al. Utilisation of maternal and child health handbook in Mongolia: A cross-sectional study. Health Education Journal. 2018;0(0):001789691775364. |
| 8 | Kobayashi S, Hanada N, Matsuzaki M, Takehara K, Ota E, Sasaki H, et al. Assessment and support during early labour for improving birth outcomes. The Cochrane database of systematic reviews. 2017;4:Cd011516. |
| 9 | Takehara K, Suto M, Kakee N, Tachibana Y, Mori R. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child abuse & neglect. 2017;70:231-9. |
| 10 | Tachibana Y, Takehara K, Kakee N, Mikami M, Inoue E, Mori R, et al. Maternal impulse control disability and developmental disorder traits are risk factors for child maltreatment. Sci Rep. 2017;7(1):15565. |
中村 秀文
| ＃ | 主な論文・総説・著書 |
|---|---|
| 1 | Davis JM, Baer GR, McCune S, Klein A, Sato J, Fabbri L, Mangili A, Short MA, Tansey S, Mangum B, Hokuto I, Nakamura H, Salaets T, Allegaert K, Yao L, Blum M, Toerner J, Turner M, Portman R; International Neonatal Consortium. Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials. J Pediatr. 2020 Apr;219:243-249.e1. doi: 10.1016/j.jpeds.2019.09.060. |
| 2 | Katsunuma T, Fujisawa T, Maekawa T, Akashi K, Ohya Y, Adachi Y, Hashimoto K, Mizuno M, Imai T, Oba MS1, Sako M, Ohashi Y, Nakamura H. Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. Allergol Int. 2019 Mar 5. pii: S1323-8930(19)30014-0. doi: 10.1016/j.alit.2019.02.001. |
| 3 | Saito J, Akabane M, Komura M, Nakamura H, Ishikawa Y; Age-Appropriate Pediatric Dosage Forms in Japan Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation. July 2018 Therapeutic Innovation and Regulatory Science. 2019 Jul;53(4):455-471. doi: 10.1177/2168479018791133 |
| 4 | Koga Y, Povalko N, Inoue E, Nakamura H, Ishi A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K: Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. 2018 Sep. J Neurol. 2018;265(12):2861-2874. doi: 10.1007/s00415-018-9057-7 |
| 5 | Mori M, Nakagawa M, Tsuchida N, Kawada K, Sato J, Sakiyama M, Hirano S, Sato K, Nakamura H. Proposal for the development of biologics in pediatric rheumatology. Pediatr Int. 2018 Feb;60(2):108-114. doi: 10.1111/ped.13495. |
| 6 | 中川雅生，土田尚，河田興，佐藤淳子，崎山美知代，平野信也，森雅亮，中村秀文： 本邦における小児医薬品開発推進のための提言．日本小児科学会雑誌，2016；120：10：25-33． |
| 7 | 松井健志，伊吹友秀，田代志門，中村秀文, 小児医薬品の早期実用化に資するレギュラトリーサイエンス研究班： 小児を対象とする臨床研究において求められる倫理的配慮の原則．日本小児科学会雑誌，2016；120：8：1-13 |
| 8 | Iijima K, Sako M, Nozu K, Nakamura H, et al: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet, 2014;384(9950): 1273-1281. doi: 10.1016/S0140-6736(14)60541-9. |
| 9 | Yoshikawa N, Nakanishi K, Sako M, Nakamura H, et al: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015;87(1):225-32. doi: 10.1038/ki.2014.260. |
| 10 | Amstutz U1, Shear NH, Rieder MJ, Nakamura H, et al: Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014;55(4):496-506. doi: 10.1111/epi.12564. |